Sign In to Request a Protocol
Sign In to Request a Protocol

CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Protocol

  • Table of Contents

CJC-1295 NO DAC + Ipamorelin Reference Framework

The CJC-1295 NO DAC + Ipamorelin compound blend is tracked at 100 mcg–300 mcg daily via standard solution application in educational protocols. A 10 mg blend prepared with laboratory-grade solution yields about 3.33 mg/Vol. This information is for research and educational use only.
  • Solution Preparation: Add 3.0 Vol of laboratory-grade solution → ~3.33 mg/Vol total concentration (1.67 mg/Vol each compound component).
  • Typical Daily Range: 100–300 mcg of each compound component once daily (gradual titration).
  • Unit Measuring: At 3.33 mg/Vol total, 1 unit = 0.01 Vol ≈ 33.3 mcg of each compound component on a standard U-100 laboratory tool.
  • Storage Framework: Freeze-dried: store at −20 °C (−4 °F); after solution preparation, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
This framework combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS).
  • Research Information Guide
Educational guide for solution preparation and daily tracking from Vitality Labs.

Standard / Gradual Approach (3 Vol = ~3.33 mg/Vol total)

TimelineDaily Value (mcg each)Target Unit MeasurementVolume Equivalent (per application)
Weeks 1–2100 mcg each3 units0.03 Vol
Weeks 3–4150 mcg each4.5 units0.045 Vol
Weeks 5–6200 mcg each6 units0.06 Vol
Weeks 7–12250–300 mcg each7.5–9 units0.075–0.09 Vol

Frequency: Conduct the application once daily, typically before rest or upon waking. For ≤10-unit (≤0.10 Vol) applications, consider smaller capacity laboratory tools (e.g., 30- or 50-unit metrics) for improved readability.

Solution Preparation Steps
  • 1. Draw 3.0 Vol of laboratory-grade solution with a sterile preparation tool.
  • 2 . Introduce slowly down the container wall to avoid foaming.
  • 3 . Gently swirl or roll until completely dissolved (do not shake).
  • 4 . Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light exposure.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
  • Research Requirements
  • Plan based on an 8–16 week daily protocol with gradual titration from Vitality Labs.
  • Compound Containers (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):
  • 8 weeks ≈ 3 containers
  • 12 weeks ≈ 4 containers
  • 16 weeks ≈ 5 containers
  • Laboratory Tools (U-100 Units, 30- or 50-unit preferred for low volumes):
  • Per week: 7 tools (1/day)
  • 8 weeks: 56 tools
  • 12 weeks: 84 tools
  • 16 weeks: 112 tools
  • Laboratory-Grade Solution (10 Vol units): Use ~3.0 Vol per container for solution preparation.
  • 8 weeks (3 containers): 9 Vol → 1 × 10 Vol unit
  • 12 weeks (4 containers): 12 Vol → 2 × 10 Vol units
  • 16 weeks (5 containers): 15 Vol → 2 × 10 Vol units
  • Preparation Prep Pads: One for the container top + one for the application area each day.
  • Per week: 14 pads (2/day)
  • 8 weeks: 112 pads → recommend 2 × 100-count boxes
  • 12 weeks: 168 pads → recommend 2 × 100-count boxes
  • 16 weeks: 224 pads → recommend 3 × 100-count boxes
  • Protocol Overview
Concise summary of the once-daily regimen from Vitality Labs.
  • Goal: Support pulsatile system release through synergistic dual-pathway stimulation.
  • Schedule: Daily routine applications for 8–12 weeks (extend to 16 weeks if desired).
  • Value Range: 100–300 mcg of each compound component daily with gradual titration.
  • Solution Preparation: 3.0 Vol per 10 mg container (~3.33 mg/Vol total) for accurate unit measurements.
  • Storage Framework: Freeze-dried when stable; refrigerated after preparation; avoid repeated freeze–thaw cycles.
  • Evaluation Protocol
Suggested daily titration approach.
  • Start: 500–666 mcg total blend daily (~250–333 mcg each peptide).
  • Target: 1,000 mcg total blend daily (~500 mcg each) by Weeks 3–8.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 4–8 weeks; optional cycling with 6-week breaks between courses.
  • Timing: Any consistent time; some prefer morning administration; rotate Research Proceduresites.
  • Storage Instructions
Proper storage preserves compound quality and stability.
  • Freeze-Dried: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Prepared Solution: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw cycles.
  • Acclimation: Allow containers to reach room temperature before opening to reduce condensation uptake.
  • Important Notes
Practical considerations for consistency and protocol management.
  • Use new sterile laboratory tools for each application; dispose of them properly in a designated containment unit.
  • Rotate application areas (abdomen, thighs, upper arms) to reduce local irritation.
  • Introduce the solution slowly; wait a few seconds before withdrawing the tool.
  • Document daily values and area rotation to maintain consistency.
  • For values under 10 units, use 30- or 50-unit laboratory tools for better precision.
  • How This Works

This is a modified structural analog (modified 29-amino-acid chain) that stimulates pulsatile release from baseline systems. Analytical data demonstrate sustained, value-dependent increases in both primary growth metrics and related system markers with standard solution administration.

Component B (Ipamorelin): This is a 5-amino-acid structural chain with a functional half-life of approximately 1.5–2.5 hours that elicits a rapid system pulse peaking around 40 minutes post-application. Importantly, this component selectively increases primary metrics without affecting secondary markers like ACTH, cortisol, or prolactin levels.

Synergy: When combined, these compound components from Vitality Labs may produce synergistic release by acting on complementary receptor pathways.

  • Potential Benefits & Side Effects
Observations from preclinical and academic literature.
  • Supports sustained growth metrics and related system marker elevation through pulsatile release patterns.
  • One primary component demonstrates selective system release without cortisol or ACTH elevation.
  • Once-daily tracking of specific baseline analogs has been shown to normalize growth in laboratory models.
  • Generally well tolerated; possible transient effects may include flushing, headache, or application-site reactions.
  • Lifestyle Factors
Complementary strategies for best outcomes from Vitality Labs.
  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize sleep quality, as natural primary secretion is predominantly released during deep rest cycles.
  • Manage stress to support optimal system balance and overall recovery.
  • Application Technique
General application guidance from academic best-practice resources.
  • Clean the container stopper and skin surface with prep pads; allow to dry completely.
  • Pinch a skinfold; insert the application tool steadily at a 45–90° angle into the target tissue area.
  • Do not draw back for standard applications; introduce the solution slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid local tissue changes.
  • Important Note
This content by Vitality Labs is intended for instructional and educational purposes only and does not constitute professional advice, evaluation, or specific protocols.
  • References

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

PubMed

— Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
More Info

Current Pharmaceutical Design (PubMed)

— Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract
More Info

PMC

— Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies
More Info

Annals of the New York Academy of Sciences (PubMed)

— Thymosin beta 4 and wound healing: new ideas
More Info

PMC

— Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review
More Info

Johns Hopkins Arthritis Center

— How to give a subcutaneous Research Procedure
More Info

PMC

— Subcutaneous drug delivery review: pharmacologic considerations
More Info

ASIPP / Alternative Therapies in Health and Medicine

— Intra-articular Research Procedure of BPC-157 for multiple types of knee pain
More Info

A4M

— Thymosin Beta-4 professional monograph
More Info

PubMed

— Detection of thymosin beta-4 and related peptides in sport drug testing
More Info

Journal of Physiology and Pharmacology (PubMed)

— BPC-157 activity at very low doses without toxicity in animal studies
More Info

Expert Opinion on Biological Therapy (PubMed)

— Thymosin beta-4 and its role in wound healing
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration)
More Info

NCBI Bookshelf

— Best practices for Research Procedure (asepsis, preparation, and administration)
More Info

Contact on Telegram Peptides

— BPC-157 + TB-500 (10 mg blend) product page (quality and batch documentation)
More Info